Back to News
Market Impact: 0.3
Dermatology Biotech Bambusa Raises $168.9 Million in US IPO
Source: Bloomberg
IPOs & SPACsHealthcare & Biotech
Bambusa Therapeutics raised $168.9 million in an upsized U.S. IPO, priced at the midpoint of its marketed range. The early-stage biotech focuses on dermatology and autoimmune diseases.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Odd Lots: What Wall Street Really Thinks About the AI Trade Now
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- Alphabet drags on Nasdaq futures as the stock faces a record post-earnings loss
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock